Biotech

All Articles

Analysts explore Avidity's DMD succeed, exposing subtleties in records

.Avidity Biosciences satisfied financiers with period 1/2 information in Duchenne muscular dystrophy...

Actinogen's cortisol blocker falls short phase 2 clinical depression research study

.Actinogen Medical's cortisol blocker has skipped the major endpoint of a period 2 research study in...

Bivictrix determines going personal only technique to take ADC into clinic

.Antibody-drug conjugates (ADCs) have gone to the center of many a billion-dollar biobuck licensing ...

TPG tops up funds to $580M for expenditures all over lifestyle sciences

.Asset manager TPG, which has sustained biotechs including Sionna Therapeutics and also Santa Clam A...

Merck quits stage 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT plan has endured another trouble. Months after shuttering a period 3 cancer ...

After a hard year, Exscientia folds up right into Recursion

.After a year determined by pipe cuts, the shift of its CEO and also discharges, Exscientia is going...

Cullinan, after $25M deal, restore bispecific to Port

.Cullinan Therapy was impressed sufficient along with Port BioMed's bispecific immune system reactor...

A more detailed check out Intense Biotech's Tough 15

.In this particular week's episode of "The Leading Pipe," our experts're diving in to Strong Biotech...

Lilly faces phase 2 failure of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's gathering celebrating the commendation of Alz...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable management hirings, shootings and al...